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Many extracellular and intracellular signals promote the c-Abl tyrosine kinase activity.
c-Abl in turn triggers a multitude of changes either in protein phosphorylation or in gene
expression in the cell. Yet, c-Abl takes part in diverse signaling routes because of several
domains linked to its catalytic core. Complex conformational changes turn on and off its
kinase activity. These changes affect surface features of the c-Abl kinase and likely its
capability to bind actin and/or DNA. Two specific inhibitors (ATP-competitive or allosteric
compounds) regulate the c-Abl kinase through different mechanisms. NMR studies show
that a c-Abl fragment (SH3–SH2-linker–SH1) adopts different conformational states upon
binding to each inhibitor. This supports an unconventional use for allosteric compounds to
unraveling physiological c-Abl signaling circuits.
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INTRODUCTION
Proteomics has revealed a rather complex picture underly-
ing cellular signaling circuits. Recent studies have indicated
an extensive overlap between diverse cellular responses. DNA
damage-induced stress response overlaps with pathogen infection
response and with heat stress in intact animals (Caenorhabditis
elegans; Ermolaeva et al., 2013). Signaling connections between
DNA damage, stress response, and aging remain elusive in other
intact organisms (Gartner and Akay, 2013). Yet, evidence from
Ermolaeva et al. (2013) supports a model of an integrated signal-
ing network at the interface of various cell stress routes.
We have discussed about the aberrant c-Abl signaling in
the molecular events at the interface of oxidative stress –
metabolic regulation, protein aggregation, and DNA damage in
neurons (Gonfloni et al., 2012). We have proposed that vari-
ous stress responses seem to rely on a small set of recurring
c-Abl-mediated regulatory circuits (Gonfloni et al., 2012). An
emerging theme in neuronal diseases is the aberrant interplay
between c-Abl phosphorylation of transcription factors, adaptors,
modifiers/enzymes, and ubiquitin-mediated signaling responses
(Gonfloni et al., 2012, Ciccone et al., 2013).
In this perspective, I will discuss how modulation of c-Abl,
through small molecule allosteric inhibitors/ligands could be
exploited to tackle the interface of c-Abl signaling circuits.
SURFING THE CELL SIGNALING CIRCUITS
Cell metabolism and homeostasis rely on signaling networks
of interacting proteins. Posttranslational modifications (PTMs)
are crucial for the network. Colocalization of the binding part-
ners converts protein interactions into functional consequences
(Kuriyan and Eisenberg, 2007). Crosstalk and interplay between
different PTMs give rise to a versatile, rich, and dynamic
framework of signaling circuits. Negative (or positive) feed-
back loops control the amplitude of signaling pathway and the
sustained activation in time, conveying signals for irreversible
decisions of the cell. A crucial issue for understanding cell sig-
naling is to define how PTMs control changes in metabolism
and homeostasis. A simple way is to consider protein domains as
basic units of cell signaling (Kuriyan and Cowburn, 1997). Cells
may use modular binding motifs like a broad device dedicated
to the selective recognition of PTMs (Seet et al., 2006). How-
ever, complex biochemical responses can be only achieved in the
context of multidomain proteins or multiprotein complexes. Of
note, PTMs can also induce a new conformational state that in
turn promotes an allosteric regulation of the targeted protein. An
example of such an allosteric modulation is the phosphorylation
of the activation loop of Src tyrosine kinases. This phosphoryla-
tion promotes the productive configuration of the catalytic site.
By this mechanism, Src activity (i.e., a productive conformation of
the active site in the catalytic domain) also controls the availability
of the regulatory domains (SH3-linker; Gonfloni et al., 2000).
This effect in turn promotes selective binding/recruitment in
multiprotein complexes.
Posttranslational modifications are dynamic and necessary
for assembling a temporary platform of local signaling circuits.
PTMs work as an allosteric device both for the modified protein
and for the assembly/(or reshaping?) of multiprotein complexes.
Enzymes are often “switchable,” with their activities controlled by
many targets/effectors. The tyrosine kinases are themselves regu-
lated by phosphorylation through various allosteric mechanisms.
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Non-receptor tyrosine kinases (RTKs) have a conserved catalytic
domain (kinase domain = SH1), auto-inhibited by the binding
of regulatory domains (SH2, SH3). Such an allosteric regulation
links the enzymatic activity of the kinase with the colocalization
of its substrate. Allosteric auto-regulation seems to be a recur-
ring feature in cell signaling (Liu and Nussinov, 2013). Protein
domains with enzymatic activity (acting as modifiers/writers) are
often in tandem with the binding motifs devoted to recognition
(acting as readers) of the same modification. This concept is
also well substantiated by ubiquitin-mediated signaling. Ubiqui-
tin represents a transferable interaction domain recognized by
specialized binding motifs (ubiquitin binding domains, UBDs).
Monoubiquitinated proteins often contain a UBD required for
their auto-regulation (Seet et al., 2006).
c-Abl IS AN ALLOSTERIC SIGNALING SWITCH FOR VARIOUS
CELL RESPONSES
Non-receptor Abl tyrosine kinases regulate a diverse range of
cellular signaling paths. Recent reviews have discussed both the
biological functions of the mammalian c-Abl tyrosine kinase
(Colicelli, 2010, Wang, 2014) and the role of Abl family kinases in
cancer (Greuber et al., 2013). It is beyond the scope of this review
discussing these aspects. Interested readers are directed to several
excellent reviews on this topic (Sirvent et al., 2008, Hossain et al.,
2012, Greuber et al., 2013, Wang, 2014).
Here, I will recall the mechanisms of c-Abl auto-inhibition.
The purpose is to highlight the effects of small molecule inhibitors
on the conformation of c-Abl.
The Abl kinase family comprises two related proteins Abl1
(c-Abl) and Abl2 (Arg). Both kinases have redundant and unique
roles due to their conserved sequence/domain structures. c-Abl
and Arg have two different variants (1a and 1b). Both variants are
ubiquitously expressed. Abl kinases share a conserved assembly
of amino-terminal regulatory and catalytic domain (SH3–SH2-
linker–SH1 domain). At the carboxyl terminus region, Abl kinases
contain a filamentous (F)-actin-binding domain (ABD; Van Etten
et al., 1994). c-Abl and Arg are less conserved in the middle
region. So, Arg lacks of the three nuclear localization signal (NLS)
motifs and localizes in the cytoplasm and in cell periphery (Miller
et al., 2004). By contrast, c-Abl is present in the cytosol but
also in organelles, such as the endoplasmic reticulum (ER) the
mitochondria (Ito et al., 2001), or the nucleus (Wen et al., 1996).
The diverse localization of c-Abl is modulated by PTMs (Yoshida
et al., 2005). The formation of distinct multiprotein complexes
is likely regulated by a dynamic spatial recruitment. Spatial dis-
tribution of c-Abl is linked to the catalytic competence of the
kinase. The latter is in constant equilibrium between low (fully
inhibited) and high (fully activated) levels of activity (Hantschel
and Superti-Furga, 2004). c-Abl signaling is not only dependent
from the outcomes derived from its enzymatic kinase activity. But,
it depends from dynamic recruitment of c-Abl into different pro-
tein complexes (and subcellular compartments). In vertebrates, its
C-terminal F-ABD mediates actin binding, bundling and micro-
tubule crosslinking (Bradley and Koleske, 2009). This has impor-
tant consequences for cell adhesion, migration (Woodring et al.,
2003), intracellular trafficking (Rotty et al., 2013), endocytosis
(Lonskaya et al., 2013), autophagy (Yogalingam and Pendergast,
2008, Hebron et al., 2013b, Lonskaya et al., 2013). In Drosophila,
D-abl signaling is linked to actin dynamics and cell adhesion
(reviewed by Lanier and Gertler, 2000, Hernandez et al., 2004).
Recent evidence indicates that the D-abl kinase signaling regulates
the Golgi complex architecture in neurons (Kannan et al., 2014).
These data suggest that some of the effects of c-Abl signaling may
arise from alterations of protein trafficking and secretion (Kannan
et al., 2014). Kinase-independent functions of c-Abl have been
already described (Henkemeyer et al., 1990, Chen et al., 2006).
Evidence supports a kinase-independent function of Drosophila
Abl for axonal guidance outcomes (O’Donnell and Bashaw, 2013).
These results are consistent with a model for stepwise scaffolding
and kinase functions of Abl in cell motility (Lapetina et al.,
2009). Likely in a stepwise manner c-Abl promotes (or prevents)
the formation of diverse signaling platforms within the cell.
Specific outcomes rely on the full catalytic competence of the
Abl kinase. The latter is due to local enrichment and/or a con-
comitant allosteric binding/removal of activators/adaptors/co-
inhibitors (as it occurs in the nucleus during apoptosis). Both
local enrichment and expression/localization of binding partners
(adaptors/co-inhibitors) depend from cellular context.
ALLOSTERIC REGULATION OF c-Abl
The auto-inhibited conformation of c-Abl is controlled through
SH3–SH2-linker unit as in the Src family tyrosine kinases. In c-
Src, the SH2 domain interacts with the C-terminal tail phospho-
tyrosine residue (Y527). By contrast, in c-Abl, the SH2 domain
interacts more intimately with the large C-terminal lobe of the
kinase domain (SH1). Interestingly, the tight interactions of the
SH2–SH1 domain are induced by the binding of the myristoylated
residues of the N-terminal region into a hydrophobic pocket
of the kinase (Figure 1; Nagar et al., 2003). c-Abl requires the
N-terminal myristoyl group (only present in Abl1b variant) to
help the proper SH3–SH2-linker docking and inhibition (Iacob
et al., 2011, Corbi-Verge et al., 2013, de Oliveira et al., 2013).
Allosteric inhibitory interactions for the Abl1a variant are still
poorly understood. Such interactions likely involve the binding
of other inhibitors/adaptors. Small molecule compounds (GNF-2
and GNF-5) targeting the myristate pocket in the C-lobe of the
FIGURE 1 | Schematics of the functional domains in c-Abl. SH3, Src
homology 3 domain: SH2, Src homology 2 domain. Y245 is in the linker
region connecting SH2 domain with the kinase domain. Y412 is in the
activation loop of the kinase domain. Phosphorylation in these two sites
may prevent the auto-inhibited conformation of the c-Abl.
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kinase domain do act as allosteric c-Abl inhibitors (Adrian et al.,
2006, Fabbro et al., 2010, Zhang et al., 2010). The relevance of
the myristoyl-binding pocket is further reinforced by the recent
discovery of small-molecule c-Abl activators that dock into the
same site (Yang et al., 2011, Hong et al., 2014). Upon c-Abl
activation and removal of the allosteric interactions, the SH2
domain interacts with the N-terminal lobe of the kinase domain
by using different surfaces of the SH2 domain (Hantschel, 2012).
Compelling evidence indicates that the SH2 domain acts as a pos-
itive allosteric activator via the formation of an internal interface
with the N-terminal lobe of kinase domain (Hantschel, 2012).
Of note, the positioning of the SH2 domain facilitates multisite
phosphorylation of substrates by c-Abl (Filippakopoulos et al.,
2008, Grebien et al., 2011). However, alternative active states of
c-Abl that do not require the SH2/kinase interface to function may
occur when local clustering of c-Abl kinase core is sufficient for
triggering transphosphorylation of the activation loop. In these
circumstances the SH2 domain displacement from the back of
the kinase domain is dispensable (Panjarian et al., 2013a,b). In
short, the multidomain kinases like c-Abl can assume various
conformational states and take more than one path to activation.
EMERGING CONCEPTS FROM THE SOLUTION
CONFORMATIONS OF c-Abl
Recent structural studies using NMR in combination with small
angle X-ray scattering (SAXS) of a c-Abl fragment (SH3–SH2-
linker–SH1 domains) provide the first structural information of
apo form of c-Abl in the absence of small molecule inhibitors
(Skora et al., 2013). The apo form of c-abl adopts the “closed”
conformation with the SH3–SH2 regulatory unit engaged with
the kinase domain. However, addition of Imatinib (an ATP-
competitive inhibitor) induces both a large structural rearrange-
ment of the kinase domain and the detachment of the SH3–SH2
regulatory unit from the kinase domain leading to the formation
of an “open” inactive state, where the ATP binding site is not
accessible. In contrast to Imatinib, addition of the myristoyl
pocket ligand GNF-5 to apo c-Abl induces only limited local
changes around the myristoyl-binding pocket and keeps the SH3–
SH2 regulatory unit in the “closed” state. Addition of GNF-5
to the “open” inactive state (c-Abl in complex with Imatinib)
restores the “closed” inactive conformation (Skora et al., 2013).
Under physiological conditions the “open” and “closed” confor-
mations of c-Abl may be in equilibrium, which can be altered
by the presence of specific inhibitors (ATP-competitive and/or
allosteric ones).
It has been proposed that the ABD may stabilize the auto-
inhibited conformation of the kinase by binding to F-actin
(Woodring et al., 2003). Interestingly, the inhibitory effect of
F-actin requires the SH2-kinase domain interaction to main-
tain the auto-inhibited conformation (Woodring et al., 2003).
Small molecule inhibitors may induce a structural remodel-
ing of the auto-inhibited conformation. This in turn may
perturb domain interactions and consequently impinge on
adaptor/effector/substrate binding, modulating c-Abl signaling
dynamics. Cells treated with Imatinib show a profound change
in the shape and a more rapid migration when plated on
collagen-coated substrates (Chen et al., 2013). GNF-2 promotes a
translocation of c-Abl to the endoplasmic reticulum (Choi et al.,
2009). It is tempting to consider that GNF-2 promotes a dynamic
recruitment of c-Abl into different subcellular compartments and
protein contexts. A timely relocalization of c-Abl/GNF-2 complex
in a specific subcellular compartment may induce per se a signal-
ing circuitry.
An unproductive conformation (“open” inactive state) of the
catalytic site induced by Imatinib may promote the availability of
the regulatory domains (SH3–SH2-linker–ABD) with profound
effects on c-Abl-interactome.
Molecular switches like c-Abl have modular domains required
for their assembly into multiprotein complexes. Yet, c-Abl has also
a modifier/kinase domain to regulate scaffold/signaling dynamics.
The challenge now is to understand how such a complex signaling
assembly is regulated in time and space (Hossain et al., 2012).
Of note, both local enrichment and expression/localization of
binding partners (adaptors/co-inhibitors) are dictated from the
cell type and signaling context.
ABERRANT c-Abl SIGNALING
The c-Abl kinase was early discovered as the oncogene in the Abel-
son murine leukemia virus (Goff et al., 1980) and then associated
with human leukemias (Ben-Neriah et al., 1986). Several reports
have indicated that c-Abl is a substrate and an activator of RTK.
This bidirectional activation contributes to robust and persistent
RTK signaling (Bromann et al., 2004). Cancer cells, expressing
high levels of c-Abl, become dependent from its catalytic activity
for growth and viability (reviewed in Greuber et al., 2013). On the
other hand, in neurons aberrant c-Abl activation causes hyper-
phosphorylation, misfolding, and protein aggregation of tau pro-
tein, or alpha-synuclein. Such effects are considered hallmarks of
neurodegenerative diseases (Ciccone et al., 2013, Tenreiro et al.,
2014).
c-Abl SIGNALING MEETS UBIQUITIN-MEDIATED RESPONSE
Cell signaling relies on PTMs for its regulation. The interplay and
the crosstalk between phosphorylation and ubiquitination repre-
sent a recurrent theme in cell signaling (Hunter, 2007). We have
discussed about some connections occurring between c-Abl phos-
phorylation and ubiquitin-mediated signaling in DNA damage
response (Maiani et al., 2011). Kinase phosphorylation/activation
often triggers ubiquitination. Activated forms of c-Abl are more
unstable than wild-type (Echarri and Pendergast, 2001).
Compelling evidence indicates that c-Abl modulates the degra-
dation of two proteins implicated in the pathogenesis of Parkin-
son’s disease (Mahul-Mellier et al., 2014). A specific inhibitor
of c-Abl like Nilotinib, used for leukemia treatment, promotes
autophagic degradation of α-synuclein while protecting neu-
rons (Hebron et al., 2013a, Lonskaya et al., 2014). Interest-
ingly, Nilotinib-induced autophagic changes increase endoge-
nous Parkin level and ubiquitination, favoring amyloid clearance
(Lonskaya et al., 2014). Taken together the data indicate that
small molecule c-Abl inhibitors (ATP-competitive) may modulate
the interplay between c-Abl and ubiquitin-mediated signaling.
Convincing evidence indicates that c-Abl-mediated phosphory-
lation directly regulates the activity of some substrate E3 ligases
(Zuckerman et al., 2009, Chan et al., 2013). In addition, negative
regulation of E3 ligase activity by c-Abl can require a specific
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recruitment of c-Abl into a complex with adaptor molecules,
necessary for proper localization (Skouloudaki and Walz, 2012).
Of note, tyrosine phosphorylation of Parkin on Y143 inhibits
its E3 ligase activity leading to an accumulation of Parkin sub-
strates (Ko et al., 2010). On the contrary, Imatinib treatment
restores the E3 ligase activity of Parkin and its protective function.
Interestingly, administration of Nilotinib has reduced the c-Abl
activation and the levels of the Parkin substrate (PARIS) without
preventing tyrosine phosphorylation of Parkin and accumulation
of the Parkin substrate AIMP2. This suggests that the protective
effect of Nilotinib may be in part Parkin-independent or related to
the pharmacodynamics properties of Nilotinib (Karuppagounder
et al., 2014). Of note, Nilotinib belongs to a second generation of
inhibitor, ATP-competitive like Imatinib. It is more potent (>20-
fold), exhibiting activity toward the majority of Imatinib-resistant
mutations. The majority of Nilotinib–c-Abl interactions overlap
with those described in the Imatinib–c-Abl complex. However,
Nilotinib binds many of mutants resistant to Imatinib and is
less sensitive to mutations of the C-lobe of the kinase (Reddy
and Aggarwal, 2012). This may reflect that Nilotinib induces a
dynamic rearrangement in the catalytic domain, attenuating the
effects of mutations on the auto-inhibited conformation.
CONCLUSION
Compelling evidence indicates the physiological relevance of the
interface between c-Abl signaling and stress response, metabolic
regulation mediated by transcription factors (Gonfloni et al.,
2012). A small molecule that binds to the myristate binding
pocket in the C-lobe of the Abl kinase was shown to inhibit Bcr-
Abl (Zhang et al., 2010). This result indicates a functional connec-
tion between the myristate pocket and the kinase active site. Data
from hydrogen exchange mass spectrometry indicate that binding
of GNF-2/GNF-5 induces a dynamic conformation of residues
near Thr315 that allows ATP-competitive inhibitors to tolerate
the isoleucine at this position (Zhang et al., 2010). However,
it remains still elusive how changes in the myristate pocket are
communicated to the ATP binding site of the kinase. Molecular
dynamic (MD) simulations (Fallacara et al., 2014) and emerging
evidence from recent structural studies using NMR indicate that
c-Abl may assume different conformational states in presence
with different small molecule inhibitors (Skora et al., 2013).
Together these data indicate that GNF-2 binding induces a more
compact conformation of SH2-kinase domain interface of c-Abl.
Therefore allosteric ligands for myristoyl pocket may be valuable
tools for tackling the interface of c-Abl signaling. They could rep-
resent a way to attenuate the enzymatic activity while impinging
on critical SH2 domain interactions. This in turn may rewire
downstream signaling circuits and/or pathways. Recent evidence
on the use of GNF-2 in vivo supports such a model (Maiani et al.,
2012). c-Abl interacts with a large number of proteins (up to now
more than 100) most of them are also c-Abl substrates (85%;
Colicelli, 2010), in line with the idea that substrates can work
as allosteric activators of the kinase. A better understanding of
the spatiotemporal regulation of c-Abl signaling may allow us to
modulate c-Abl signaling into specific subcellular compartments,
with important consequences for cell homeostasis. These studies
will take advantage from small allosteric compounds/activators as
tools to investigate the biological functions of c-Abl (Hong et al.,
2014). Surely, a detailed understanding of c-Abl functions will
help to develop combined targeted therapies in order to rewire
the physiological regulatory circuits in cancer cells and in aged
neurons.
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